BC Week In Review | Dec 23, 2013
Company News

AstraZeneca, Bristol-Myers deal

AstraZeneca will acquire full ownership of the diabetes business it shares with Bristol-Myers. BMS will receive $2.7 billion up front and is eligible for up to $1.4 billion in regulatory and sales milestones, plus royalties...
BioCentury | Dec 23, 2013
Strategy

Diabetes take over

Increased competition and heavy discounting required by commercial insurance plans have led Bristol-Myers Squibb Co. to off-load its entire late-stage and marketed diabetes portfolio to partner AstraZeneca plc . On Dec. 19, the companies announced AZ...
BC Extra | Dec 20, 2013
Top Story

Bristol-Myers selling diabetes stake to AZ

AstraZeneca plc (LSE:AZN; NYSE:AZN) will acquire full ownership of the diabetes business it shares with Bristol-Myers Squibb Co. (NYSE:BMY). BMS will receive $2.7 billion up front and is eligible for up to $1.4 billion in...
BC Week In Review | Jan 7, 2013
Company News

Bristol-Myers, Takeda deal

On Dec. 24, 2012, Takeda said it and Amylin Pharmaceuticals Inc. mutually terminated a 2009 deal to co-develop and commercialize obesity compounds. In 2011, the companies discontinued development of pramlintide/metreleptin based on a "commercial reassessment"...
BC Extra | Dec 27, 2012
Company News

Takeda, Amylin terminate obesity deal

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it and Amylin Pharmaceuticals Inc. mutually terminated a 2009 deal to co-develop and commercialize obesity compounds. In 2011, the companies discontinued development of pramlintide/metreleptin based on a "commercial reassessment"...
BC Week In Review | Jul 9, 2012
Company News

Amylin, Bristol-Myers deal

Bristol-Myers Squibb will spend about $7 billion to acquire Amylin, including $5.3 billion for Amylin stock and $1.7 billion to pay off the biotech's debt and a contractual obligation. Following the acquisition, Bristol-Myers will fold...
BioCentury | Jul 9, 2012
Strategy

Triple play in diabetes

The addition of Amylin Pharmaceuticals Inc. 's glucagon-like peptide 1 franchise will give partners Bristol-Myers Squibb Co. and AstraZeneca plc three modern mechanisms in their commercial diabetes portfolio and five in the pipeline - more than...
BC Extra | Jul 3, 2012
Top Story

Bristol-Myers to acquire Amylin

Bristol-Myers Squibb Co. (NYSE:BMY) will spend about $7 billion to acquire Amylin Pharmaceuticals Inc. (NASDAQ:AMLN), including $5.3 billion for Amylin stock and $1.7 billion to pay off the biotech's debt and a contractual obligation. Following...
BioCentury | Nov 14, 2011
Strategy

Betting on Bydureon

After its split from Eli Lilly and Co. , Amylin Pharmaceuticals Inc. plans to go it alone in the U.S. diabetes market. To compete with the large pharmas that dominate the space, the biotech is banking...
BioCentury | Oct 3, 2011
Finance

Few Cinderellas this time

Big caps suffered the least in a very ugly quarter. But that's not saying much: biotechs with market caps of more than $5 billion were still down 10% as a group in 3Q, while other...
Items per page:
1 - 10 of 245